Klaus Fuglsang Kofoed

Professor, Heart Centre, Rigshospitalet

Klaus Fuglsang Kofoed is a clinical professor specializing in cardiology at the Department of Clinical Medicine. He is an expert in non-invasive cardiac imaging, including Cardiac CT, PET, SPECT, and echocardiography, as well as ambulatory ECG and invasive coronary angiography. His research focuses on ischemic heart disease, myocardial glucose metabolism, cardiovascular risk assessment, coronary physiology, heart failure, and valvular heart disease.
He serves as the principal investigator for multiple clinical trials, including the VERDICT trial, the DYNAMITE trial, the DANE-HEART trial, and the CGPS-progress study. He also leads the CT research initiative within the Copenhagen General Population Study (CGPS). In addition, he is a Steering Committee Member for the DISCHARGE trial, an EU-funded study on diagnostic imaging strategies for coronary artery disease, as well as for the Inter99 cohort study and the InterVitaminK trial. Furthermore, he is Co-Chair of the ARTICHOKE study and a member of the EDITORS (East Danish IniTiative On Revascularization Strategy) Group.
His expertise and leadership in cardiovascular research contribute to advancements in diagnostic imaging and treatment strategies, particularly in ischemic heart disease and cardiac physiology.

Herlev and Gentofte Hospital

Herlev and Gentofte Hospital is a leading research institution where specialised research is deeply integrated with clinical practice across all departments. The hospital is internationally recognised for advanced research in cardiopulmonary diseases, focusing on heart failure, arrhythmias, and pulmonary conditions, as well as in oncology, with innovative studies in cancer diagnostics, immunotherapy, and personalized treatment strategies. Dermatology and allergology research are also prominent, addressing chronic skin conditions, autoimmune diseases, and allergy mechanisms. The hospital’s strong academic environment is supported by extensive collaborations with national and international universities, local authorities, and pharmaceutical companies, fostering continuous innovation and improvements in patient care.

Se publikationer her